Targeting of human interferon antagonists
US10947288B2 · kind B2 · utility
3Cited by
5References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 14, 2018 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Aug 23, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.